In this week's video, Mike Cintolo, chief analyst of Cabot Top Ten Trader and Cabot Growth Investor, shares his latest thoughts on the state of the market after Friday's numerous market-moving events. He's still cautious, holding a good chunk of cash, but is remaining...
Read More
With earnings season largely over most of our stocks are now moving based on news that affects the broad market, and less on company-specific trends, with a few exceptions.
Read More
In this week's video, Mike Cintolo, chief analyst of Cabot Top Ten Trader and Cabot Growth Investor, shares his latest thoughts on the state of the market after Friday's numerous market-moving events. He's still cautious, holding a good chunk of cash, but is remaining...
Read More
The market was mostly quiet (though also mostly positive) for the first four days of the week, though volatility picked up today after some additional tariffs from China and Fed Chair Jerome Powell’s speech in Wyoming.
Read More
A Spanish news outlet, Intereconomia.com, is reporting that biotech company Amgen (AMGN) is in talks to buy Alexion Pharmaceuticals (ALXN) for close to $200 per share.
Read More
From Cabot Top Ten Trader
Despite all the moves of the past couple of weeks and today’s headlines, nothing has really changed with our overall view. Looking at the primary evidence, the market’s intermediate-term trend has yet to turn positive—all major indexes continue to around...
Read More
When the market develops the next clear uptrend (and it could be coming soon), you'll want to buy these three future growth stock leaders.
Read More
Remain generally cautious given that our Cabot Tides are still negative, though you shouldn’t be outright defensive given the encouraging action from so many growth stocks.
Read More
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
The market seems to be rebounding and stabilizing after a tumultuous couple of weeks. The escalation of trade tensions, a sputtering global economy and talk of the next recession spooked investors. But as fear wanes investors realize that money has no place else go...
Read More
There's a lot of mystery and misinformation out there about options trading. Here are five common misconceptions - and what the real truth is.
Read More
Let me tell you about the greatest options trade I saw in my 10 years on the Chicago Board of Options Exchange (CBOE) - and what I learned from it.
Read More
Last week's near-record Argentina stock market crash was a long time coming. It's a lesson in what red flags to look for when investing in emerging markets.
Read More
The market remains strong and I continue to recommend that you be heavily invested in a well-diversified portfolio that meets your investment needs.
Read More
The best mid-cap stocks to buy now share similar traits: good business models and reliable sales and earnings growth. Here are three that come to mind.
Read More
Today’s and next week’s issues of Cabot Undervalued Stocks Advisor are going to look a bit different. I won’t be reviewing all of our portfolio stocks today. Many Wall Street analysts are on vacation, so there will be very little in the way changes...
Read More
I break the best investment sites for small-cap investors into three categories: idea generation, stock analysis, idea capture. Here are a few that I like.
Read More
Our second recommendation is taking profits on a previous idea.
Read More
Six analysts have raised their EPS estimates for our first pick today, a consumer finance company.
Read More
Reliable dividend stocks may seem obvious and boring. But if you buy them and hang on to them, they can make your future. Here are five that stand out now.
Read More
